摘要:
A method to reduce the aldehyde content of a pine chemical composition is disclosed. The pine chemical composition is selected from gum turpentine, gum rosin, CST BLS, CTO, depitched CTO, DTO, TOH, TOR, TOP, TOFA, fractionated TOFA, TOFA dimer, TOFA trimer, TOFA monomer, isostearic acid, stearic acid, and ester- and amide derivatives thereof. The pine chemical composition is treated with an aldehyde scavenger such as anthranilamide at a temperature between 20 °C to 300 °C, for 1 minute to 5 hours.
摘要:
The subject invention provides "no sat" canola oil. The subject invention also provides seeds that can be used to produce such oils. Plants that produce these seeds are also included within the subject invention. All of this was surprisingly achieved by using a delta-9 desaturase gene in canola. This technology can be applied to other plants as disclosed herein. Oils of the subject invention have particularly advantageous characteristics and fatty acid profiles, which were not heretofore attained. The subject invention still further provides a plant-optimized delta-9 desaturase gene. The subject invention still further provides a plant-optimized delta-9 desaturase gene. In some preferred embodiments, a preferred plant comprises at least two copies of a delta-9 desaturase gene of the subject invention. Seeds produced by such plants surprisingly do not exhibit effects of gene silencing but rather have further surprising reductions in levels of total saturates.
摘要:
In one embodiment, the invention is to a catalyst composition, comprising vanadium and titanium. Preferably, the molar ratio of vanadium to titanium in an active phase of the catalyst composition is greater than 0.5:1.
摘要:
The subject application relates to methods of treatment of peripheral vascular disease (PVD) as well as ischemic osteonecrosis, peritoneal ischemia, chronic ocular disease, macular degeneration, or diabetic retinopathy, comprising administering a therapeutically effective amount of a trans carotenoid. The invention also relates to the use of such carotenoids as pretreatments for mammals at risk of an ischemic event.
摘要:
Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: enantiomers, diastereomers, solvates, or salts thereof, wherein A, W, X and Z are defined herein.